JP2024533457A5 - - Google Patents
Info
- Publication number
- JP2024533457A5 JP2024533457A5 JP2024515863A JP2024515863A JP2024533457A5 JP 2024533457 A5 JP2024533457 A5 JP 2024533457A5 JP 2024515863 A JP2024515863 A JP 2024515863A JP 2024515863 A JP2024515863 A JP 2024515863A JP 2024533457 A5 JP2024533457 A5 JP 2024533457A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- antigen
- multispecific antibody
- binding region
- isolated multispecific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163243493P | 2021-09-13 | 2021-09-13 | |
| US63/243,493 | 2021-09-13 | ||
| EP21202685 | 2021-10-14 | ||
| EP21202685.0 | 2021-10-14 | ||
| PCT/IB2022/058572 WO2023037333A1 (en) | 2021-09-13 | 2022-09-12 | CD33 X Vδ2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024533457A JP2024533457A (ja) | 2024-09-12 |
| JP2024533457A5 true JP2024533457A5 (cg-RX-API-DMAC7.html) | 2025-09-18 |
Family
ID=83509005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024515863A Pending JP2024533457A (ja) | 2021-09-13 | 2022-09-12 | がんの治療のためのCD33×Vδ2多重特異性抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240409634A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4402171A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024533457A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240055002A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022344595A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3229822A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202328193A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023037333A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10501540B2 (en) | 2014-04-10 | 2019-12-10 | Lava Therapeutics B.V. | Immunoglobulins binding human Vγ9 Vδ2 T cell receptors |
| AR134580A1 (es) | 2023-12-08 | 2026-01-28 | Janssen Biotech Inc | ANTICUERPOS DE CD33, ANTICUERPOS MULTIESPECÍFICOS DE CD33 / Vd2 Y USOS DE ESTOS |
| US20260103515A1 (en) | 2024-08-08 | 2026-04-16 | Janssen Biotech, Inc. | DOSES AND PHARMACEUTICAL COMPOSITIONS OF A CD33 x Vd2 BISPECIFIC ANTIBODY FOR THE TREATMENT OF CANCER |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US20100081792A1 (en) | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
| US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| FR2879605B1 (fr) | 2004-12-16 | 2008-10-17 | Centre Nat Rech Scient Cnrse | Production de formats d'anticorps et applications immunologiques de ces formats |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| DK1999154T3 (da) | 2006-03-24 | 2012-12-03 | Merck Patent Gmbh | Fremstillede heterodimere proteindomæner |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| AU2008343589A1 (en) | 2007-12-19 | 2009-07-09 | Centocor Ortho Biotech Inc. | Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| EP2282769A4 (en) | 2008-04-29 | 2012-04-25 | Abbott Lab | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES |
| CN102282168A (zh) | 2008-11-18 | 2011-12-14 | 梅里麦克制药股份有限公司 | 人血清白蛋白接头以及其结合物 |
| AU2010229705A1 (en) | 2009-03-27 | 2011-10-20 | Zymogenetics, Inc. | Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| KR101224468B1 (ko) | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | 신규한 형태의 이중표적항체 및 그 용도 |
| PT2560993T (pt) | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| WO2012023053A2 (en) | 2010-08-16 | 2012-02-23 | Novimmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
| EP2420253A1 (en) | 2010-08-20 | 2012-02-22 | Leadartis, S.L. | Engineering multifunctional and multivalent molecules with collagen XV trimerization domain |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| IN2014CN03887A (cg-RX-API-DMAC7.html) | 2011-10-27 | 2015-10-16 | Genmab As | |
| US9574010B2 (en) | 2011-11-04 | 2017-02-21 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| US9527927B2 (en) | 2011-12-20 | 2016-12-27 | Medimmune, Llc | Modified polypeptides for bispecific antibody scaffolds |
| WO2013157953A1 (en) | 2012-04-20 | 2013-10-24 | Merus B.V. | Methods and means for the production of ig-like molecules |
| DK2924052T3 (da) | 2012-11-21 | 2019-09-30 | Pharmabcine Inc | Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme |
| PT2970980T (pt) | 2013-03-15 | 2018-11-19 | Janssen Biotech Inc | Métodos de produção para controlor o teor de lisina c-terminal, galactose e ácido siálico em proteínas recombinantes |
| US10501540B2 (en) | 2014-04-10 | 2019-12-10 | Lava Therapeutics B.V. | Immunoglobulins binding human Vγ9 Vδ2 T cell receptors |
| CN109843926B (zh) | 2016-09-30 | 2023-01-20 | 豪夫迈·罗氏有限公司 | 针对cd3的双特异性抗体 |
| JOP20190116A1 (ar) * | 2018-05-24 | 2019-11-24 | Janssen Biotech Inc | الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها |
| JP7457007B2 (ja) * | 2018-09-19 | 2024-03-27 | ラヴァ・セラピューティクス・エヌ・ヴイ | 二重作用CD1d免疫グロブリン |
| EP3792283A1 (en) * | 2019-09-16 | 2021-03-17 | Lava Therapeutics B.V. | Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies |
| PE20231517A1 (es) * | 2020-03-13 | 2023-09-28 | Janssen Biotech Inc | Materiales y metodos para la union de siglec-3/cd33 |
-
2022
- 2022-09-12 KR KR1020247008425A patent/KR20240055002A/ko active Pending
- 2022-09-12 EP EP22778072.3A patent/EP4402171A1/en active Pending
- 2022-09-12 JP JP2024515863A patent/JP2024533457A/ja active Pending
- 2022-09-12 WO PCT/IB2022/058572 patent/WO2023037333A1/en not_active Ceased
- 2022-09-12 US US18/691,254 patent/US20240409634A1/en active Pending
- 2022-09-12 CA CA3229822A patent/CA3229822A1/en active Pending
- 2022-09-12 TW TW111134256A patent/TW202328193A/zh unknown
- 2022-09-12 AU AU2022344595A patent/AU2022344595A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115551888B (zh) | 抗cd73抗体及其用途 | |
| TWI769537B (zh) | 標靶bcma的抗體、雙專一性抗體及其用途 | |
| CN114181310B (zh) | 抗tigit抗体、其药物组合物及用途 | |
| KR102068600B1 (ko) | Pdl-1 항체, 그 약학적 조성물 및 그 용도 | |
| US20220010018A1 (en) | MONOCLONAL ANTIBODIES AGAINST IgV DOMAIN OF B7-H3 AND USES THEREOF | |
| JP2020501531A5 (cg-RX-API-DMAC7.html) | ||
| AU2007324509B2 (en) | Novel antiproliferation antibodies | |
| WO2020160560A2 (en) | Anti-claudin 18 antibodies and methods of use thereof | |
| JP2021510736A5 (cg-RX-API-DMAC7.html) | ||
| JP7851303B2 (ja) | ヒトcd3イプシロンに結合する新規なヒト抗体 | |
| CN116041530A (zh) | 多特异性抗体及其制备和使用方法 | |
| CN114981301B (zh) | Pd1和vegfr2双结合剂 | |
| JP2024532489A5 (cg-RX-API-DMAC7.html) | ||
| EP4545569A2 (en) | Binding protein having h2l2 and hcab structures | |
| IL321280A (en) | Anti-cmet antibody, antibody-drug conjugate, and preparation method therefor and use thereof | |
| AU2019306113B2 (en) | Anti-human PD-L1 antibodies and their uses | |
| JP2025516590A5 (cg-RX-API-DMAC7.html) | ||
| CN121013865A (zh) | 抗cd180结合分子及其用途 | |
| JP2024540536A5 (cg-RX-API-DMAC7.html) | ||
| US20260022165A1 (en) | Antibodies targeting cell surface deposited complement protein c3d and use thereof | |
| HK40066348B (en) | Antibody targeting bcma, bispecific antibody, and use thereof | |
| WO2025228406A1 (zh) | 结合ly6g6d的分子及其用途 | |
| WO2025140548A1 (zh) | 一种免疫缀合物及其用途 | |
| HK40014714A (en) | Anti-gprc5d antibody and molecule containing same | |
| HK1132752B (en) | Novel antiproliferation antibodies |